<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">— ...

VRTX

Vertex Reports Second Quarter 2026 Financial Results

Vertex raises 2026 guidance as Crinetics deal advances and pipeline expands

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot; class=&quot;bwalignc&quot;&gt;
&lt;i xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;— ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Vertex posted stronger quarterly results, lifting 2026 revenue guidance to $13.1–$13.2B and highlighting broader growth from CF, SCD, beta thalassemia, and acute pain. The pending Crinetics acquisition adds a fifth pillar focused on rare endocrine diseases, potentially driving long-term value but introducing integration and financing considerations. The company also notes continued ALYFTREK uptake and emerging contributions from CASGEVY and JOURNAVX.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Total Q2 2026 revenue $3.33B, up 12% YoY.</li><li>Raising 2026 revenue guidance to $13.1–13.2B.</li><li>Crinetics acquisition agreement; closing anticipated Q3 2026, value ~$10B.</li><li>Povetacicept PDUFA date set for Nov 30, 2026.</li><li>ALYFTREK uptake expanding; CASGEVY/JOURNAVX contribute to growth; 25 countries reimbursed.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Vertex Pharmaceuticals Incorporated (VRTX)</strong>: Reported Q2 2026 results; raised full-year 2026 revenue guidance; Crinetics acquisition expanding growth vector.</li><li><strong>Crinetics Pharmaceuticals (CRNX)</strong>: Vertex to acquire for $85/ share; closing expected Q3 2026; adds rare endocrine diseases pillar.</li></ul>
  </section>

  <section data-block="category">
    <h3>M&amp;A</h3>
    <p>Category fits M&amp;A within Corporate Developments, reflecting Vertex’s strategy to diversify beyond CF via the Crinetics deal while confirming execution on the earnings and product-area growth plan.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Crinetics acquisition closing anticipated in Q3 2026; potential near-term re-rating.</li><li>Raised 2026 revenue guidance supports multiple expansion and optionality.</li><li>ALYFTREK and JOURNAVX uptake broaden Vertex’s revenue mix.</li><li>PDUFA date for povetacicept in IgAN set for Nov 30, 2026; nephrology catalysts.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 2026 total revenue $3.33B, up 12% YoY.</li><li>U.S. revenue $2.06B (+11%), international $1.28B (+14%).</li><li>Full-year 2026 revenue guidance raised to $13.1–$13.2B.</li><li>Povetacicept BLA: PDUFA date November 30, 2026.</li><li>Crinetics acquisition closing anticipated in Q3 2026; equity value ~$10B.</li><li>Cash, cash equivalents and marketable securities: $13.6B as of 6/30/2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on VRTX over 6–12 months as Crinetics closes and revenue guidance raises.</p>
  </section>
</section>


<article>
  <section>
    <p><strong>Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.</strong> The company highlighted solid growth across its cystic fibrosis portfolio and diversification into new disease areas, while signaling continued strategic momentum with an anticipated acquisition of Crinetics Pharmaceuticals, expected to close in the third quarter of 2026. The press release also notes a PDUFA date for povetacicept of November 30th.</p>
  </section>

  <section>
    <h2>Executive Commentary</h2>
    <p>"Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "With this breadth of commercial and clinical opportunities, we look forward to bringing more medicines to more patients around the globe and in so doing, creating long-term value."</p>
  </section>

  <section>
    <h2>Second Quarter 2026 Highlights</h2>
    <ul>
      <li>— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 —</li>
      <li>— Raising full-year revenue guidance to $13.1 billion to $13.2 billion —</li>
      <li>— Continued progress across research and development pipeline; povetacicept PDUFA date November 30th —</li>
      <li>— Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026 —</li>
    </ul>
    <p><strong>Total revenue</strong> increased 12% to $3.33 billion compared to the second quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas. In the U.S., total revenue increased 11% to $2.06 billion due to continued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY and JOURNAVX. Outside the U.S., total revenue increased 14% to $1.28 billion due to strong CF performance across multiple geographies, including ALYFTREK uptake; increased CASGEVY infusions; and a favorable impact from foreign exchange.</p>

    <p><strong>Combined GAAP and non-GAAP R&amp;D, Acquired IPR&amp;D and SG&amp;A expenses</strong> were $1.6 billion and $1.4 billion, respectively, in the second quarter of 2026, compared to $1.4 billion and $1.2 billion, respectively, for the second quarter of 2025. These increases were primarily due to commercial investment to support the launch of JOURNAVX in acute pain and the build-out of the renal franchise, led by povetacicept in IgAN.</p>

    <p><strong>GAAP and non-GAAP effective tax rates</strong> were 21.0% and 21.1%, respectively, compared to 19.5% and 19.4%, respectively, for the second quarter of 2025.</p>

    <p><strong>GAAP and non-GAAP net income</strong> were $1.1 billion and $1.2 billion, respectively, compared to $1.0 billion and $1.2 billion, respectively, for the second quarter of 2025, as a result of increased product revenue, partially offset by increased operating expenses.</p>

    <p><strong>Cash, cash equivalents, and total marketable securities</strong> as of June 30, 2026, were $13.6 billion, compared to $12.3 billion as of December 31, 2025. The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex’s common stock pursuant to its share repurchase program.</p>
  </section>

  <section>
    <h2>Full-Year 2026 Financial Guidance</h2>
    <p>Vertex today raised its full year 2026 total revenue guidance to <strong>$13.1 billion to $13.2 billion</strong> from <strong>$12.95 billion to $13.1 billion</strong> previously. Embedded in this guidance are expectations for continued growth in CF, including the continued global uptake of ALYFTREK and TRIKAFTA, as well as <strong>$500 million or more</strong> in revenue from non-CF products, namely CASGEVY and JOURNAVX. Total revenue guidance continues to reflect a year-over-year benefit of approximately <strong>150 basis points</strong> in growth from foreign exchange rates, net of Vertex’s foreign exchange hedging program. Vertex reiterated its full year 2026 guidance for combined GAAP and non-GAAP R&amp;D, AIPR&amp;D, and SG&amp;A expenses of <strong>$6.3 billion to $6.45 billion</strong> and <strong>$5.65 billion to $5.75 billion</strong>, respectively. This guidance also continues to include an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations.</p>

    <p>Vertex’s financial guidance for 2026 does not reflect the impact of the pending acquisition of Crinetics Pharmaceuticals. Vertex continues to anticipate completion of the acquisition in the third quarter of 2026, subject to customary closing conditions, and will provide updated guidance for 2026 following transaction close.</p>

    <p>Vertex’s financial guidance is summarized below:</p>

    <p>Note: The accompanying table was provided in the release with more detail on the guidance metrics; the narrative above outlines the current posture for 2026 guidance and the expected impact of foreign exchange, CF growth drivers, and non-CF contributions.</p>
  </section>

  <section>
    <h2>Strategic Update: Crinetics Acquisition</h2>
    <p>Vertex entered into an agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026. This transaction is expected to broaden Vertex’s portfolio into rare endocrine diseases, reinforcing Vertex’s strategy to diversify beyond CF and grow across multiple therapeutic areas as a long-term value driver for shareholders, including holders of VRTX stock.</p>
  </section>
</article>

Vertex posted stronger quarterly results, lifting 2026 revenue guidance to $13.1–$13.2B and highlighting broader growth from CF, SCD, beta thalassemia, and acute pain. The pending Crinetics acquisition adds a fifth pillar focused on rare endocrine diseases, potentially driving long-term value but introducing integration and financing considerations. The company also notes continued ALYFTREK uptake and emerging contributions from CASGEVY and JOURNAVX.

News insight

Vertex Reports Second Quarter 2026 Financial Results

AI summary

Sentiment rationale

Key facts

M&A